OPRM1 blocking peptide

OPRM1 Antibody (Center) Blocking Peptide

• Gene Names: OPRM1; MOP; MOR; LMOR; MOR1; OPRM; M-OR-1
• Synonyms: OPRM1; OPRM1 Antibody (Center) Blocking Peptide; Mu-type opioid receptor; M-OR-1; MOR-1; Mu opiate receptor; Mu opioid receptor; MOP; hMOP; MOR1; OPRM1 blocking peptide

• Specificity: The synthetic peptide sequence used to generate the antibody was selected from the Center region of human OPRM1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
• Form/Format: Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.
• Sequence Length: 400

• Cellular Location: Cell membrane; Multi-pass membrane protein
• Tissue Location: Expressed in brain. Isoform 16 and isoform 17 are detected in brain.
• Preparation and Storage: Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C.

Related Product Information for OPRM1 blocking peptide

Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta- gamma dimer activating downstream cellular effectors. The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extend to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15. They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B. Also couples to adenylate cyclase stimulatory G alpha proteins. The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization. Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction. The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins. The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist- specific receptor phosphorylation. Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling. Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling. Endogenous ligands induce rapid desensitization, endocytosis and recycling whereas morphine induces only low desensitization and endocytosis. Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties. Involved in neurogenesis. Isoform 12 couples to GNAS and is proposed to be involved in excitatory effects. Isoform 16 and isoform 17 do not bind agonists but may act through oligomerization with binding- competent OPRM1 isoforms and reduce their ligand binding activity.

NCBI and Uniprot Product Information

• NCBI GI #: 2851402
• NCBI GeneID: 4988
• UniProt Accession #: P35372; Q12930; Q4VWM1; Q4VWM2; B0FXJ1; B2R9S7; B8Q1L7; B8Q1L8; B8Q1L9; E7EWZ3; G8XRH6; G8XRH8
• Molecular Weight: 20,188 Da
• NCBI Official Full Name: Mu-type opioid receptor
• NCBI Official Synonym Full Names: opioid receptor mu 1
• NCBI Official Symbol: OPRM1
• NCBI Official Synonym Symbols: MOP; MOR; LMOR; MOR1; OPRM; M-OR-1
• NCBI Protein Information: mu-type opioid receptor
• UniProt Protein Name: Mu-type opioid receptor
• Protein Family: Mu-type opioid receptor
• UniProt Gene Name: OPRM1
• UniProt Synonym Gene Names: MOR1; M-OR-1; MOR-1; MOP; hMOP
• UniProt Entry Name: OPRM_HUMAN

NCBI Description

This gene encodes one of at least three opioid receptors in humans; the mu opioid receptor (MOR). The MOR is the principal target of endogenous opioid peptides and opioid analgesic agents such as beta-endorphin and enkephalins. The MOR also has an important role in dependence to other drugs of abuse, such as nicotine, cocaine, and alcohol via its modulation of the dopamine system. The NM_001008503.2:c.118A>G allele has been associated with opioid and alcohol addiction and variations in pain sensitivity but evidence for it having a causal role is conflicting. Multiple transcript variants encoding different isoforms have been found for this gene. Though the canonical MOR belongs to the superfamily of 7-transmembrane-spanning G-protein-coupled receptors some isoforms of this gene have only 6 transmembrane domains. [provided by RefSeq, Oct 2013]

Uniprot Description

MOR-1: a Gi-protein-coupled receptor for beta-endorphin, morphine and other opiates. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Ligand-binding inactivates adenylyl cyclase, and activates a variety of G-beta-gamma-dependent pathways including the MAPK and the PI3K/Akt cascades. Two splice-variant isoforms have been described.

Protein type: GPCR, family 1; Membrane protein, multi-pass; Membrane protein, integral; Receptor, GPCR

Chromosomal Location of Human Ortholog: 6q24-q25

Cellular Component: endoplasmic reticulum; Golgi apparatus; integral to plasma membrane; neuron projection; plasma membrane

Molecular Function: beta-endorphin receptor activity; G-protein alpha-subunit binding; G-protein beta-subunit binding; G-protein coupled receptor activity; neuropeptide binding; protein binding; voltage-gated calcium channel activity

Biological Process: behavioral response to ethanol; cellular response to stress; G-protein signaling, coupled to cyclic nucleotide second messenger; G-protein signaling, coupled to IP3 second messenger (phospholipase C activating); negative regulation of adenylate cyclase activity; negative regulation of cell proliferation; positive regulation of neurogenesis; sensory perception of pain; synaptic transmission

Disease: Epilepsy, Idiopathic Generalized